The notes were due Thursday. On Tuesday, Tenon Medical paid them off in full — two days before the deadline, and with a stated reason: to stop the holders from converting the debt into new shares at a price set below what the stock was trading.
According to an amended 8-K filed with the SEC, the notes were convertible into common stock at a price equal to 80% of the average trading price over the prior three days — meaning every share issued through conversion would carry a 20% discount to market. Each discounted share makes the ones already outstanding worth a smaller slice of the same company. Tenon's early cash repayment, announced in an 8-K filed with the SEC on September 9, ended that possibility. The notes carried an aggregate principal of about $5.16 million and had been issued six months earlier, in March 2026, according to the filing.
For an existing shareholder, the difference between cash repayment and conversion is concrete: cash leaves the share count unchanged; conversion hands a discounted stake to the note holders at everyone else's expense. The company chose to pay.
Shares closed 117.21% higher at $5.3000 on the maturity date after the announcement, on dollar volume of about $584 million across roughly 933,000 trades.
"By proactively addressing this obligation, we are reducing potential dilution for our shareholders," said Steven M. Foster, chief executive officer and president, in the company's September 9 press release.
The free float stands at about 534,000 shares, roughly 80% of shares outstanding. Short volume on the session — the number of shares sold short during Thursday's trading, not total outstanding short positions — was about 32 million shares, or about 59% of reported volume. Both figures come from the same session: a free float of about 534,000 shares, and roughly 32 million shares of short-side activity.
The same filing's boilerplate lists the company's ability to continue as a going concern and its ability to regain compliance with Nasdaq listing standards among the subjects it has made forward-looking statements about. Neither is addressed in the press release.